Summit Therapeutics touts a rare triumph over Keytruda in lung cancer from a China-only Phase 3 study

Andrew Dunn

Senior Biopharma Correspondent

Hours before America’s biggest cancer conference starts in Chicago, a small biotech may have stolen the show, touting late-stage results in a Thursday afternoon press …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Summit Therapeutics touts a rare triumph over Keytruda in lung cancer from a China-only Phase 3 study

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Sum­mit Ther­a­peu­tics touts a rare tri­umph over Keytru­da in lung can­cer from a Chi­na-on­ly Phase 3 study

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

Summit Therapeutics touts a rare triumph over Keytruda in lung cancer from a China-only Phase 3 study

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence